Ta strona została przetłumaczona automatycznie i dokładność tłumaczenia nie jest gwarantowana. Proszę odnieść się do angielska wersja za tekst źródłowy.

A Study to Learn About How Well the Medicine Efgartigimod Works to Treat Autoimmune Encephalitis In Children 12 Years or Older and Adults (Polaris)

7 maja 2026 zaktualizowane przez: argenx

A Global, Multicenter, Randomized, Double-Blinded, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy, Safety, and Tolerability of Efgartigimod PH20 SC in Adult and Adolescent Participants With Autoimmune Encephalitis

The POLARIS study is designed to evaluate how well efgartigimod PH20 SC may work (called "efficacy") and how safe it is for people diagnosed with Autoimmune Encephalitis (AIE). The study consists of 4 parts: in part A participants will receive efgartigimod SC; in part B, participants will be randomized to receive either efgartigimod SC or placebo; in part C, participants who completed part B will receive efgartigimod SC; in part D, participants who completed part C will be observed after their last dose of efgartigimod SC. If AIE symptoms return, efgartigimod SC treatment may be restarted during this time.

The maximum overall study duration for participants is up to 3 years. More information can be found in clinicaltrials.argenx.com/polaris

Przegląd badań

Status

Jeszcze nie rekrutacja

Warunki

Interwencja / Leczenie

Szczegółowy opis

The study is designed to address the unmet need for effective immunomodulatory therapy in AIE, enrolling patients across multiple antibody-defined subgroups, with the anti-NMDAR encephalitis group serving as the primary cohort for statistical analysis.

Typ studiów

Interwencyjne

Zapisy (Szacowany)

170

Faza

  • Faza 2

Kontakty i lokalizacje

Ta sekcja zawiera dane kontaktowe osób prowadzących badanie oraz informacje o tym, gdzie badanie jest przeprowadzane.

Kontakt w sprawie studiów

Kryteria uczestnictwa

Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.

Kryteria kwalifikacji

Wiek uprawniający do nauki

  • Dziecko
  • Dorosły
  • Starszy dorosły

Akceptuje zdrowych ochotników

Nie

Opis

Inclusion Criteria:

  • Is at least 12 years of age.
  • Meeting at least the criteria for possible AIE according to the Graus criteria.
  • Part A:

Must not have received prior treatment for AIE with PLEX or Ig (participants may have received glucocorticoids); and must not have received PLEX or Ig for any other medical condition in the last 3 months

- Part B: Either completing Part A, or If directly entering Part B, must have received first-line treatment for AIE (i.e. corticosteroids, PLEX, and/or Ig) and have a CASE score of 3 or higher, or a score of 2 or higher in a single sub-item

Exclusion Criteria:

  • Known anti-myelin oligodendrocyte glycoprotein (anti-MOG) antibody positivity.
  • Any medical condition that would interfere with an accurate assessment of clinical symptoms of AIE.
  • Recent major surgery (within 3 months of screening) or intention to have major surgery during the study, except for surgeries for AIE-related teratomas and thymomas.
  • History (within 12 months before screening) of current alcohol, drug (including recreational or prescribed cannabinoids), or medication abuse.
  • Psychiatric or cognitive impairment unrelated to AIE.

Plan studiów

Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.

Jak projektuje się badanie?

Szczegóły projektu

  • Główny cel: Leczenie
  • Przydział: Randomizowane
  • Model interwencyjny: Przydział równoległy
  • Maskowanie: Potroić

Broń i interwencje

Grupa uczestników / Arm
Interwencja / Leczenie
Eksperymentalny: Part A (Open-Label Lead-in Period): Efgartigimod PH20 SC
All participants will receive efgartigimod PH20 SC open label for 8 weeks
Biologiczny: Efgartigimod PH20 (ARGX-113) SC
subcutaneous administrations of efgartigimod PH20 SC given by prefilled syringe (PFS). For participants aged 12 to <18 years with body weight ≤50 kg, the study drug will be administered by vial and syringe.
Eksperymentalny: Part B (Double-blinded treatment period): Efgartigimod PH20 SC
Participants will receive efgartigimod PH20 SC for 24 weeks
Biologiczny: Efgartigimod PH20 (ARGX-113) SC
subcutaneous administrations of efgartigimod PH20 SC given by prefilled syringe (PFS). For participants aged 12 to <18 years with body weight ≤50 kg, the study drug will be administered by vial and syringe.
Komparator placebo: Part B (Maintenance double-blinded treatment period): Placebo PH20 SC
Participants will receive placebo for 24 weeks
Inny: Placebo PH20 SC

subcutaneous administrations of placebo PH20 SC given by prefilled syringe (PFS). For participants aged 12 to <18 years with body weight

≤50 kg, the study drug will be administered by vial and syringe
Eksperymentalny: Part C (Open-Label Extension Period): Efgartigimod PH20 SC
Participants who complete Part B will receive efgartigimod PH20 SC for 24 weeks
Biologiczny: Efgartigimod PH20 (ARGX-113) SC
subcutaneous administrations of efgartigimod PH20 SC given by prefilled syringe (PFS). For participants aged 12 to <18 years with body weight ≤50 kg, the study drug will be administered by vial and syringe.

Co mierzy badanie?

Podstawowe miary wyniku

Miara wyniku
Opis środka
Ramy czasowe
Change in CASE score in the NMDAR population
Ramy czasowe: up to week 24
CASE= Clinical Assessment Scale in Autoimmune Encephalitis; NMDAR=N-methyl-D-aspartate receptor; Neuropsychological Status. The CASE (Clinical Assessment Scale in AIE) includes an assessment of 9 items: seizure, memory dysfunction, psychiatric symptoms, consciousness, language problems, dyskinesia/dystonia, gait instability and ataxia, brainstem dysfunction, weakness. This overall CASE total score ranges from 0 to 27, with a higher score indicating a greater degree of disability.
up to week 24

Miary wyników drugorzędnych

Miara wyniku
Opis środka
Ramy czasowe
Change in mRS
Ramy czasowe: up to week 8
The mRS (modified Rankin Scale) is commonly used to measure the degree of disability or dependence in the daily activities of people with neurological disabilities. Scores range from 0 (no symptoms) to 6(dead).
up to week 8
Change in CASE score
Ramy czasowe: up to week 8
The CASE (Clinical Assessment Scale in AIE) includes an assessment of 9 items: seizure, memory dysfunction, psychiatric symptoms, consciousness, language problems, dyskinesia/dystonia, gait instability and ataxia, brainstem dysfunction, weakness. This overall CASE total score ranges from 0 to 27, with a higher score indicating a greater degree of disability.
up to week 8
Change in MoCA total score
Ramy czasowe: up to week 8
MoCA= Montreal Cognitive Assessment
up to week 8
Change in NPI-C total score
Ramy czasowe: up to week 8
The NPI-C (Neuropsychiatric Inventory--Clinician) total score will be used as a global measure of neuropsychiatric symptoms.Total score is calculated by summing the scores of all the individual domains.Each domain score is determined by summing the item scores within that domain. The NPI-C uses a clinician rating method, where ratings for frequency, severity, and caregiver distress are provided for each item.These item scores are then summed to create a total domain score.
up to week 8
Change from baseline in CGI-S
Ramy czasowe: up to week 8

Expression of Change. CGI is a clinician-rated scale that measures illness severity (CGI-S) and global improvement or change (CGI-C).It is rated on a 7-point scale, from 1 (normal) to 7 (amongst the most severely ill patients) for CGI-S and from 1 (very much improved) to 7 (very much worse) for CGI-C.

PGI-S and PGI-C are the patient-reported counterparts to CGI-S and CGI-C, respectively.
up to week 8
Change from baseline in PGI-S
Ramy czasowe: up to week 8
A Impression of Severity; PGI-S= Patient Global Impression Scale. PGI-S and PGI-C are the patient-reported counterparts to CGI-S and CGI-C, respectively.
up to week 8
Change from baseline in CGI-C
Ramy czasowe: up to week 8

CGI-C= Clinical Global Expression of Change . CGI is a clinician-rated scale that measures illness severity (CGI-S) and global improvement or change (CGI-C).It is rated on a 7-point scale, from 1 (normal) to 7 (amongst the most severely ill patients) for CGI-S and from 1 (very much improved) to 7 (very much worse) for CGI-C.

PGI-S and PGI-C are the patient-reported counterparts to CGI-S and CGI-C, respectively.
up to week 8
Change from baseline in PGI-C
Ramy czasowe: up to week 8
A Impression of Severity; PGI-C= Patient Global Expression of Change . PGI-S and PGI-C are the patient-reported counterparts to CGI-S and CGI-C, respectively.
up to week 8
Incidence and severity of AEs
Ramy czasowe: up to week 8
AEs= Adverse Effects
up to week 8
Incidence and severity of SAEs
Ramy czasowe: up to week 8
SAEs = Serious Adverse Effects
up to week 8
Trough efgartigimod serum concentrations over time
Ramy czasowe: up to week 8
up to week 8
Percent change from baseline in total IgG levels in serum over time
Ramy czasowe: up to week 8
IgG= Immunoglobulin G
up to week 8
Incidence and prevalence of ADA against efgartigimod in serum over time
Ramy czasowe: up to week 8
ADA = antidrug antibody(ies)
up to week 8
Incidence and prevalence of antibodies against rHuPH20 in plasma over time
Ramy czasowe: up to week 8
rHuPH20 = Recombinant Human Hyaluronidase PH20
up to week 8
Change in mRS in the NMDAR population
Ramy czasowe: up to week 24
The mRS (modified Rankin Scale) is commonly used to measure the degree of disability or dependence in the daily activities of people with neurological disabilities. Scores range from 0 (no symptoms) to 6(dead)
up to week 24
Change in NPI-C total score in the NMDAR population
Ramy czasowe: up to week 24
NPI-C=Neuropsychiatric Inventory-Clinician; NMDAR=N-methyl-D-aspartate receptor. The NPI-C (Neuropsychiatric Inventory--Clinician) total score will be used as a global measure of neuropsychiatric symptoms. Total score is calculated by summing the scores of all the individual domains. Each domain score is determined by summing the item scores within that domain. The NPI-C uses a clinician rating method, where ratings for frequency, severity, and caregiver distress are provided for each item.These item scores are then summed to create a total domain score.
up to week 24
Change in RBANS in the NMDAR population
Ramy czasowe: up to week 24
RBANS=Repeatable Battery for the Assessment of Neuropsychological Status; NMDAR=N-methyl-D-aspartate receptor. The RBANS (Repeatable Battery for the Assessment of Neuropsychological Status) is a performance outcome measure developed to identify and characterize cognitive impairment by assessing an individual's current level of cognitive performance.
up to week 24
Percentage of CASE responders in the NMDAR population.
Ramy czasowe: at week 24
CASE = Clinical Assessment Scale in AIE ; NMDAR=N-methyl-D-aspartate receptor
at week 24
Change in CASE score in the non-NMDAR population
Ramy czasowe: up to week 24
CASE = Clinical Assessment Scale in AIE; NMDAR=N-methyl. The CASE (Clinical Assessment Scale in AIE) includes an assessment of 9 items: seizure,memory dysfunction, psychiatric symptoms, consciousness, language problems, dyskinesia/dystonia, gait instability and ataxia, brainstem dysfunction, weakness. This overall CASE total score ranges from 0 to 27, with a higher score indicating a greater degree of disability.
up to week 24
Change in RBANS in the non-NMDAR population
Ramy czasowe: up to week 24
RBANS= Repeatable Battery for the Assessment of Neuropsychological Status; NMDAR=N-methyl-D-aspartate receptor. The RBANS (Repeatable Battery for the Assessment of Neuropsychological Status) is a performance outcome measure developed to identify and characterize cognitive impairment by assessing an individual's current level of cognitive performance.
up to week 24
Change in NPI-C total score in the non-NMDAR population
Ramy czasowe: up to week 24
NPI-C= Neuropsychiatric Inventory-Clinician; NMDAR=N-methyl-D-aspartate receptor. The NPI-C Neuropsychiatric Inventory--Clinician) total score will be used as a global measure of neuropsychiatric symptoms. Total score is calculated by summing the scores of all the individual domains. Each domain score is determined by summing the item scores within that domain. The NPI-C uses a clinician rating method, where ratings for frequency, severity, and caregiver distress are provided for each item.
up to week 24
Change in mRS in the non-NMDAR population
Ramy czasowe: up to week 24
mRS= modified Rankin Scale; NMDAR=N-methyl-D-aspartate receptor. The mRS (modified Rankin Scale) is commonly used to measure the degree of disability or dependence in the daily activities of people with neurological disabilities.Scores range from 0 (no symptoms) to 6 (dead).
up to week 24
Percentage of CASE responders in the non-NMDAR population.
Ramy czasowe: at week 24
CASE = Clinical Assessment Scale in AIE ; NMDAR=N-methyl-D-aspartate receptor. The CASE (Clinical Assessment Scale in AIE) includes an assessment of 9 items: seizure, memory dysfunction, psychiatric symptoms, consciousness, language problems, dyskinesia/dystonia, gait instability and ataxia, brainstem dysfunction, weakness. This overall CASE total score ranges from 0 to 27, with a higher score indicating a greater degree of disability.
at week 24
Incidence and severity of AEs
Ramy czasowe: week 24 onwards
AEs = Adverse Effects
week 24 onwards
Incidence and severity of SAEs
Ramy czasowe: week 24 onwards
SAEs = Serious Adverse Effects
week 24 onwards
Proportion of participants with presence of neuropsychiatric symptoms, defined by NPI-C total score of at least 1 point
Ramy czasowe: at week 24
NPI-C= Neuropsychiatric Inventory-Clinician. The NPI-C (Neuropsychiatric Inventory--Clinician) total score will be used as a global measure of neuropsychiatric symptoms. Total score is calculated by summing the scores of all the individual domains. Each domain score is determined by summing the item scores within that domain. The NPI-C uses a clinician rating method, where ratings for frequency, severity, and caregiver distress are provided for each item.
at week 24
Change in MoCA total score
Ramy czasowe: up to week 24
MoCA= Montreal Cognitive Assessment
up to week 24
Proportion of participants with a favorable outcome in mRS where favorable outcome is defined as no worsening for participants with a baseline mRS score of ≤2 or improvement of ≥1 point for participants with a baseline mRS score of >2
Ramy czasowe: up to week 24
mRS=modified Rankin Scale. The mRS (modified Rankin Scale) is commonly used to measure the degree of disability or dependence in the daily activities of people with neurological disabilities. Scores range from 0 (no symptoms) to 6 (dead).
up to week 24
Change in CGI-S
Ramy czasowe: up to week 24
CGI-S= Clinical Global Impression of Severity. CGI is a clinician-rated scale that measures illness severity (CGI-S) and global improvement or change (CGI-C).It is rated on a 7-point scale, from 1 (normal) to 7 (amongst the most severely ill patients) for CGI-S and from 1 (very much improved) to 7 (very much worse) for CGI-C.
up to week 24
Change in CGI-C
Ramy czasowe: up to week 24
CGI-C= Clinical Global Impression of Change. CGI is a clinician-rated scale that measures illness severity (CGI-S) and global improvement or change (CGI-C).It is rated on a 7-point scale, from 1 (normal) to 7 (amongst the most severely ill patients) for CGI-S and from 1 (very much improved) to 7 (very much worse) for CGI-C.
up to week 24
Change in PGI-C
Ramy czasowe: week 0 to week 24
PGI-C =Patient Global Expression of Change. PGI-S and PGI-C are the patient-reported counterparts to CGI-S and CGI-C, respectively.
week 0 to week 24
Change in PGI-S
Ramy czasowe: week 0 to week 24
PGI-S= Patient Global Expression of Severity. PGI-S and PGI-C are the patient-reported counterparts to CGI-S and CGI-C, respectively.
week 0 to week 24
Time to resolution of status epilepticus
Ramy czasowe: up to 24 weeks
up to 24 weeks
Time to first occurrence of seizure freedom.
Ramy czasowe: up to 24 weeks
Seizure freedom is defined as no seizures for at least 28 consecutive days
up to 24 weeks
Proportion of participants with seizure freedom for at least the 28 consecutive days
Ramy czasowe: up to 24 weeks
up to 24 weeks
Time to use of rescue therapy after randomization
Ramy czasowe: up to 24 weeks
up to 24 weeks
Trough efgartigimod serum concentrations over time
Ramy czasowe: up to 24 weeks
up to 24 weeks
Percent change in total IgG levels in serum
Ramy czasowe: up to 24 weeks
IgG = Immunoglobulin G
up to 24 weeks
Incidence and prevalence of ADA against efgartigimod in serum over time
Ramy czasowe: up to 24 weeks
ADA = anti drug antibodies
up to 24 weeks
Incidence and prevalence of antibodies against rHuPH20 in plasma over time
Ramy czasowe: up to 24 weeks
rHuPH20 = Recombinant Human Hyaluronidase PH20
up to 24 weeks
Change in CASE score in the NMDAR population compared with the non-NMDAR population
Ramy czasowe: up to 24 weeks
CASE = Clinical Assessment Scale in AIE ; NMDAR=N-methyl-D-aspartate receptor. . The CASE (Clinical Assessment Scale in AIE) includes an assessment of 9 items: seizure, memory dysfunction, psychiatric symptoms, consciousness, language problems, dyskinesia/dystonia, gait instability and ataxia, brainstem dysfunction, weakness. This overall CASE total score ranges from 0 to 27, with a higher score indicating a greater degree of disability.
up to 24 weeks
Change in RBANS total score
Ramy czasowe: week 24 to week 48
The RBANS (Repeatable Battery for the Assessment of Neuropsychological Status) is a performance outcome measure developed to identify and characterize cognitive impairment by assessing an individual's current level of cognitive performance.
week 24 to week 48
Percentage of participants with maintained change in the CASE total score (defined as stable or improving)
Ramy czasowe: week 24 to week 48
The CASE (Clinical Assessment Scale in AIE) includes an assessment of 9 items: seizure, memory dysfunction, psychiatric symptoms, consciousness, language problems, dyskinesia/dystonia, gait instability and ataxia, brainstem dysfunction, weakness. This overall CASE total score ranges from 0 to 27, with a higher score indicating a greater degree of disability.
week 24 to week 48
Percentage of participants with maintained mRS score (defined as stable or improving)
Ramy czasowe: week 24 to week 48
The mRS (modified Rankin Scale) is commonly used to measure the degree of disability or dependence in the daily activities of people with neurological disabilities. Scores range from 0 (no symptoms) to 6 (dead).
week 24 to week 48
Change in NPI-C total score
Ramy czasowe: week 24 to week 48
The NPI-C (Neuropsychiatric Inventory--Clinician) total score will be used as a global measure of neuropsychiatric symptoms.Total score is calculated by summing the scores of all the individual domains. Each domain score is determined by summing the item scores within that domain. The NPI-C uses a clinician rating method, where ratings for frequency, severity, and caregiver distress are provided for each item. These item scores are then summed to create a total domain score.
week 24 to week 48
Proportion of participants requiring rescue or second-line AIE therapies
Ramy czasowe: week 24 to week 48
AIE = Auto-Immune Encephalitis
week 24 to week 48
Time to participants requiring rescue or second-line AIE therapies
Ramy czasowe: week 24 to week 48
AIE = Auto-Immune Encephalitis
week 24 to week 48
Change in CASE
Ramy czasowe: week 24 to week 48
The CASE (Clinical Assessment Scale in AIE) includes an assessment of 9 items: seizure, memory dysfunction, psychiatric symptoms, consciousness, language problems, dyskinesia/dystonia, gait instability and ataxia, brainstem dysfunction, weakness. This overall CASE total score ranges from 0 to 27, with a higher score indicating a greater degree of disability.
week 24 to week 48
Change in mRs
Ramy czasowe: week 24 to week 48
The mRS (modified Rankin Scale) is commonly used to measure the degree of disability or dependence in the daily activities of people with neurological disabilities. Scores range from 0 (no symptoms) to 6 (dead).
week 24 to week 48
Change in RBANS
Ramy czasowe: week 24 to week 48
The RBANS (Repeatable Battery for the Assessment of Neuropsychological Status) is a performance outcome measure developed to identify and characterize cognitive impairment by assessing an individual's current level of cognitive performance.
week 24 to week 48
Time to resolution of status epilepticus
Ramy czasowe: week 24 to week 48
week 24 to week 48
Proportion of participants with seizure freedom for at least the 28 consecutive days preceding the participants in final Part of trial
Ramy czasowe: week 24 to week 48
mRS=modified Rankin Scale
week 24 to week 48
Incidence and prevalence of ADA against efgartigimod in serum
Ramy czasowe: week 24 to week 48
ADA = antidrug antibody(ies)
week 24 to week 48
Percent change in total IgG levels in serum
Ramy czasowe: week 24 to week 48
IgG = Immunoglobulin G
week 24 to week 48

Współpracownicy i badacze

Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.

Sponsor

argenx

Daty zapisu na studia

Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.

Główne daty studiów

Rozpoczęcie studiów (Szacowany)

13 lipca 2026

Zakończenie podstawowe (Szacowany)

4 grudnia 2030

Ukończenie studiów (Szacowany)

26 lipca 2031

Daty rejestracji na studia

Pierwszy przesłany

7 maja 2026

Pierwszy przesłany, który spełnia kryteria kontroli jakości

7 maja 2026

Pierwszy wysłany (Rzeczywisty)

13 maja 2026

Aktualizacje rekordów badań

Ostatnia wysłana aktualizacja (Rzeczywisty)

13 maja 2026

Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości

7 maja 2026

Ostatnia weryfikacja

1 maja 2026

Więcej informacji

Terminy związane z tym badaniem

Słowa kluczowe

Dodatkowe istotne warunki MeSH

Inne numery identyfikacyjne badania

  • ARGX-113-22-AIE-2001

Plan dla danych uczestnika indywidualnego (IPD)

Planujesz udostępniać dane poszczególnych uczestników (IPD)?

NIE

Informacje o lekach i urządzeniach, dokumenty badawcze

Bada produkt leczniczy regulowany przez amerykańską FDA

Tak

Bada produkt urządzenia regulowany przez amerykańską FDA

Nie

Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .

Badania kliniczne na Autoimmunologiczne zapalenie mózgu (AE)

Badania kliniczne na Efgartigimod PH20 (ARGX-113) SC

Wyszukaj podobne próby

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

CROs by country

CROs in Jordan

Warunki

Rzadkie choroby

Interwencje lekowe

Suplementy diety

Sponsor / Współpracownicy

Lokalizacje

Subskrybuj